{"url":"https://lda.senate.gov/api/v1/filings/23e37a4f-259c-4f3a-aef8-176db5cfbded/","filing_uuid":"23e37a4f-259c-4f3a-aef8-176db5cfbded","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2018,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/23e37a4f-259c-4f3a-aef8-176db5cfbded/print/","filing_document_content_type":"text/html","income":"30000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Dan Burton","dt_posted":"2019-01-22T12:26:47.723000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12141 East 79th Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Indianapolis","registrant_state":"IN","registrant_zip":"46236","registrant":{"id":401103789,"url":"https://lda.senate.gov/api/v1/registrants/401103789/","house_registrant_id":null,"name":"DAN BURTON INTERNATIONAL LLC","description":"Governmental affairs consulting.","address_1":"12141 East 79th Street","address_2":null,"address_3":null,"address_4":null,"city":"Indianapolis","state":"IN","state_display":"Indiana","zip":"46236","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAN BURTON","contact_telephone":"+1 317-507-6074","dt_updated":"2024-01-15T13:00:16.348787-05:00"},"client":{"id":200146,"url":"https://lda.senate.gov/api/v1/clients/200146/","client_id":51,"name":"GRANULES USA INC.","general_description":"Pharmaceutical distribution and sales.","client_government_entity":false,"client_self_select":null,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-09-17"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Consultant shall pursue an effort to obtain from the United States Food and Drug Administration (FDA) expeditious processing of Client's petition to allow additional sources of API, the active ingredient in ibuprofen, to enter the American market in order to alleviate an anticipated shortage.","foreign_entity_issues":"Granules India Limited","lobbyists":[{"lobbyist":{"id":62837,"prefix":null,"prefix_display":null,"first_name":"DAN","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":"United States Representative","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}